Sterling Capital Management LLC Has $527,000 Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Sterling Capital Management LLC lifted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 8,619.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,562 shares of the specialty pharmaceutical company’s stock after buying an additional 14,395 shares during the period. Sterling Capital Management LLC’s holdings in Supernus Pharmaceuticals were worth $527,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC raised its stake in Supernus Pharmaceuticals by 101.1% during the third quarter. FMR LLC now owns 16,903 shares of the specialty pharmaceutical company’s stock worth $527,000 after acquiring an additional 8,499 shares in the last quarter. HighTower Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter valued at approximately $264,000. Stifel Financial Corp increased its position in Supernus Pharmaceuticals by 1.6% during the 3rd quarter. Stifel Financial Corp now owns 69,134 shares of the specialty pharmaceutical company’s stock worth $2,156,000 after purchasing an additional 1,093 shares in the last quarter. Barclays PLC lifted its stake in Supernus Pharmaceuticals by 88.3% in the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after purchasing an additional 51,005 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after buying an additional 74,438 shares in the last quarter.

Supernus Pharmaceuticals Stock Up 0.2 %

Shares of Supernus Pharmaceuticals stock opened at $30.76 on Friday. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of 28.75 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $40.28. The company’s fifty day moving average is $32.92 and its 200 day moving average is $35.02.

Insider Activity

In other news, VP Padmanabh P. Bhatt sold 700 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the sale, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,103.38. This represents a 6.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at $307,444.95. This represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,104 shares of company stock valued at $440,263. Company insiders own 9.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SUPN. Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.